Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -80.37
- Piotroski Score 3.00
- Grade Outperform
- Symbol (APTO)
- Company Aptose Biosciences Inc.
- Price $0.37
- Changes Percentage (-4.19%)
- Change -$0.02
- Day Low $0.36
- Day High $0.39
- Year High $3.32
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, which is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS; and APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. It has agreements with CrystalGenomics, Inc. and OHM Oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/07/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$6.09
- Trailing P/E Ratio -0.15
- Forward P/E Ratio -0.15
- P/E Growth -0.15
- Net Income $-51,207,000
Income Statement
Quarterly
Annual
Latest News of APTO
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Toronto Raptors president Masai Ujiri is carrying a lot these days: Koreen
Masai Ujiri, Toronto Raptors president, mourned the passing of Dikembe Mutombo during the team's media day. Ujiri reflected on Mutombo's legacy and the impact of their work in Africa....
By The New York Times | 4 days ago -
Five things to know ahead of Raptors training camp | Globalnews.ca
The Toronto Raptors have started their pre-season training camp in Montreal. Coach Rajakovic organized mini-camps over the summer for team bonding. The team added young prospects from the NBA Draft an...
By Global News | 4 days ago -
Five Takeaways From Raptors Media Day 2024
The NBA season kicks off with 28 teams starting fresh. Toronto Raptors focus on a rebuild, defense, and player development. Scottie Barnes emerges as a leader, while Masai Ujiri emphasizes team shapin...
By Forbes | 5 days ago
